Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2025 Jul 31;17(7):4376-4378.
doi: 10.21037/jtd-2025-452. Epub 2025 Jul 29.

Robust evidence of the rapid efficacy of benralizumab

Tatsuya Nagano  1
Affiliations
Editorial

Robust evidence of the rapid efficacy of benralizumab

Tatsuya Nagano. J Thorac Dis. .
No abstract available

Keywords: Asthma; acute eosinophilic attack; benralizumab.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-2025-452/coif). T.N. reports lecture fees from AstraZeneca. The author has no other conflicts of interest to declare.

Comment on

Similar articles

See all similar articles

References

    1. Dagher R, Kumar V, Copenhaver AM, et al. Novel mechanisms of action contributing to benralizumab's potent anti-eosinophilic activity. Eur Respir J 2022;59:2004306. 10.1183/13993003.04306-2020 - DOI - PMC - PubMed
    1. Mace EM, Dongre P, Hsu HT, et al. Cell biological steps and checkpoints in accessing NK cell cytotoxicity. Immunol Cell Biol 2014;92:245-55. 10.1038/icb.2013.96 - DOI - PMC - PubMed
    1. Nowak RM, Parker JM, Silverman RA, et al. A randomized trial of benralizumab, an antiinterleukin 5 receptor α monoclonal antibody, after acute asthma. Am J Emerg Med 2015;33:14-20. 10.1016/j.ajem.2014.09.036 - DOI - PubMed
    1. Ramakrishnan S, Camp JR, Vijayakumar B, et al. The Use of Benralizumab in the Treatment of Near-Fatal Asthma: A New Approach. Am J Respir Crit Care Med 2020;201:1441-3. 10.1164/rccm.202001-0093LE - DOI - PMC - PubMed
    1. Ramakrishnan S, Russell REK, Mahmood HR, et al. Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a double-blind, double-dummy, active placebo-controlled randomised trial. Lancet Respir Med 2025;13:59-68. 10.1016/S2213-2600(24)00299-6 - DOI - PubMed

LinkOut - more resources